SLC16A10

Across TCGA pan-cancer cohorts, SLC16A10 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of SLC16A10’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SLC16A10 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SLC16A10 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, PDAC, and LUAD are the cancer types where SLC16A10 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC16A10 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	−0.994	<.001	9	view →
PDAC	Male	All	−2.611	<.001	7	view →
LUAD	All	All	−0.538	.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

SLC16A10–CCRCC

Open the CCRCC breakdown →